Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,200 shares, a drop of 14.3% from the October 15th total of 1,400 shares. Based on an average daily volume of 36,300 shares, the days-to-cover ratio is presently 0.0 days.

Bavarian Nordic A/S Stock Performance

OTCMKTS:BVNRY traded down $1.35 during trading hours on Friday, reaching $8.13. The company’s stock had a trading volume of 178,302 shares, compared to its average volume of 33,515. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 18.48 and a beta of 1.71. The firm has a 50-day simple moving average of $10.78 and a 200-day simple moving average of $9.84. Bavarian Nordic A/S has a 1 year low of $6.84 and a 1 year high of $14.60.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last announced its quarterly earnings results on Thursday, August 22nd. The company reported $0.16 earnings per share (EPS) for the quarter. The business had revenue of $205.99 million for the quarter. Bavarian Nordic A/S had a net margin of 11.50% and a return on equity of 12.50%. Equities analysts anticipate that Bavarian Nordic A/S will post 0.57 earnings per share for the current fiscal year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.